{"filing":{"accession_number":"0001665988-26-000041","cik":"0001665988","ticker":"BVS","company_name":"Bioventus Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"bvs-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000041/bvs-20260805.htm"},"events":[{"id":25203,"run_id":22868,"accession_number":"0001665988-26-000041","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Bioventus issued a press release on August 5, 2026 announcing Q2 and six-month financial results for the period ended June 27, 2026, with revenue of $153.2 million (4% growth) and GAAP earnings of $0.47 per diluted share, while reaffirming full-year 2026 guidance.","company_name":"Bioventus Inc.","ticker":"BVS","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25964,"accession_number":"0001665988-26-000041","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Bioventus issued a press release on August 5, 2026 announcing financial results for Q2 and six months ended June 27, 2026, disclosing revenue of $153.2 million (4% growth), GAAP earnings of $0.47 per diluted share, and reaffirming full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is the designated Item for results of operations and financial condition disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:18:52.677494+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25204,"run_id":22868,"accession_number":"0001665988-26-000041","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Bioventus announced initiation of a formal strategic alternatives review following receipt of an unsolicited acquisition proposal and multiple expressions of interest, with the Board establishing a committee of independent directors supported by financial advisors (Evercore) and legal counsel (Latham \u0026 Watkins) to evaluate options including a potential sale or continued standalone execution.","company_name":"Bioventus Inc.","ticker":"BVS","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25965,"accession_number":"0001665988-26-000041","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Bioventus announced initiation of a formal strategic alternatives review following receipt of an unsolicited acquisition proposal and multiple expressions of interest. The Board established a committee of independent directors with financial and legal advisors (Evercore and Latham \u0026 Watkins) to evaluate options including a potential sale of the company or continued standalone execution. This is a material M\u0026A-related disclosure under Item 8.01, as the company is actively exploring a potential change of control transaction in response to external acquisition interest.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:18:52.677494+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25964,"accession_number":"0001665988-26-000041","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Bioventus issued a press release on August 5, 2026 announcing financial results for Q2 and six months ended June 27, 2026, disclosing revenue of $153.2 million (4% growth), GAAP earnings of $0.47 per diluted share, and reaffirming full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is the designated Item for results of operations and financial condition disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:18:52.677494+00:00","company_name":"Bioventus Inc.","ticker":"BVS","filing_date":"2026-08-05"},{"id":25965,"accession_number":"0001665988-26-000041","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Bioventus announced initiation of a formal strategic alternatives review following receipt of an unsolicited acquisition proposal and multiple expressions of interest. The Board established a committee of independent directors with financial and legal advisors (Evercore and Latham \u0026 Watkins) to evaluate options including a potential sale of the company or continued standalone execution. This is a material M\u0026A-related disclosure under Item 8.01, as the company is actively exploring a potential change of control transaction in response to external acquisition interest.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:18:52.677494+00:00","company_name":"Bioventus Inc.","ticker":"BVS","filing_date":"2026-08-05"}]}